Specific and nonspecific Ag-presentation by B cells was examined for the sensitivity to the treatment with emetin, an irreversible protein synthesis inhibitor. For this aim, A20-HL B lymphoma cells expressing surface IgM receptors specific for TNP were used as APC. OVA and TNP-OVA were used as nonspecific and specific Ag, respectively. The treatment with emetin greatly impaired the ability of A20-HL cells to present specific Ag, but not nonspecific Ag, to 42-6A cloned T cells specific for OVA. The ability of the emetin-treated A20-HL cells to present nonspecific Ag indicates that the treated cells are able to process nonspecific Ag and to present processed Ag. Ag binding and the internalization by A20-HL cells through surface receptors were not affected by the emetin treatment. A20-HL cells took up specific Ag for stimulation of 42-6A cells in the presence of cycloheximide, a reversible protein synthesis inhibitor. These results suggest that the action of emetin is localized to the intracellular processing of specific Ag, not of nonspecific Ag. Thus, the processing pathway for specific Ag seems to be different from that for nonspecific Ag.